HealthcareMid capRs 7,488 crRs 36.2 cr traded a day
Close on 10 September 2026
825.75
−0.47%
52-week range79% of the way up
591.95888.70
Market cap
7,488 cr
P/E (TTM)
35.1×
industry 45×
EPS (TTM)
23.51
Revenue YoY
+38.7%
Q1 FY27
Profit YoY
+53.8%
Net margin
14.2%
+1.4pt vs a year ago
Growth trend
+35.4pt
vs last quarter’s YoY
1 month
-7.1%
Below 52w high
7.6%
RSI (14)
53
Daily swing
4.1%
average true range
Volume
0.6×
vs 20-day average
Traded
Rs 36 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Above the median
+14.4%
One-year return
Around the median
-8.3%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
+38.7%
Below the 52-week high
from the highest close of the year
-7.1%
1 week
−4.88%
1 month
−7.08%
3 months
+28.89%
6 months
+25.87%
1 year
−8.25%
The read
written from the numbers on this page
The evidence leans constructive7 supporting, 1 against, 0 worth knowing
Supporting
trading 14% above its 200-day average
matches growth that is speeding up, which has beaten the market by +0.79 points over 20 sessions across 57,921 past signals
5 of the scans it matches have a positive measured record
4 independent kinds of evidence agree today, which is uncommon
revenue grew 39% year on year in the quarter ending 30 June 2026
net margin has widened from 6.7% to 14.2% across four quarters
priced at 35× earnings against an industry median of 45× — 21% below its peers
Against
down 8% over twelve months
Worth knowing
nothing the data supports either way
What would change this read: a close below 722, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working6
Net profit rose 53.8% year on year, from Rs 50 cr to Rs 76 cr.
+53.8%Rs 50 crRs 76 cr
Revenue rose 38.7% year on year, from Rs 386 cr to Rs 536 cr.
+38.7%Rs 386 crRs 536 cr
Profit grew faster than revenue, +53.8% against +38.7%.
+53.8%+38.7%
Trading 14.4% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+14.4%
Turned up over three months while the year is still negative.
+28.9% 3M-8.3% 1Y
3 different kinds of evidence point at it tonight, not 3 versions of the same one.
3 families
Needs watching
Nothing on this side tonight — not in the filings and not in the price.
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 3 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
7 of 47 matched on 10 Sep
AARTIPHARM matches 7 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
AARTIPHARM trades at 35× trailing earnings, above its median of 29× over this window — 23% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · Analyst call filings were typically +0.11pt vs the market over the next 5 sessions (n=4,339)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 39% against the same quarter a year earlier
profit rose 54% year on year
net margin widened from 10.5% to 14.2%
revenue rose in 3 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
536
94
76
8.40
14.2%
Q4 FY26
31 Mar · consolidated
583
76
61
6.74
10.5%
Q3 FY26
31 Dec · consolidated
432
58
48
5.29
11.1%
Q2 FY26
30 Sep · consolidated
418
39
28
3.08
6.7%
Q1 FY26
30 Jun · consolidated
386
67
50
5.46
12.8%
Q4 FY25
31 Mar · consolidated
564
115
88
9.75
15.7%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+7.5%
Versus 200-day average+14.4%
Below 52-week high-7.1%
Above 52-week low+39.5%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)52.6
Higher closes in last 52 of 5
Six-month return+25.87%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)4.07%
Volume versus 20-day0.6x
Median daily turnoverRs 36.2 cr
Peers
Healthcare · 68 classified companies
AARTIPHARM trades at 35.1× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — cheaper than them, by 21%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.